Time filter

Source Type

Cheshire, CT, United States

Alexion Pharmaceuticals is the original developer and distributor of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and Paroxysmal nocturnal hemoglobinuria .The company is also involved in research with regards to the immune system and how it can be stopped from attacking healthy tissue .Soliris, the company's sole marketed drug, has been approved for use in the EU and Japan however availability in other places such as the USA and Canada is limited due to marketing restrictions and lack of ensured access .In 2013 36% of sales originated in the US down from 37%, with 33% coming from Europe down from 35%; Japan accounts for just over 10%. In 2013 revenue was impacted by higher unit volumes for Soliris , and a negative price impact related to rebates in Europe; acquisition related costs fell significantly from $22 million to just $5 million. In 2011 50% of the increase in assets came from cash and cash equivalents, the value of which has since gone down since part of it was spent on acquiring Enobia. In the last quarter, R&D spending was higher due to expansion of development programs while net sales of Soliris increased 45% to $227.6 million on account of new international patients with paroxysmal nocturnal hemoglobinuria. By September 2013 quarterly sales of Soliris topped $400 million. Wikipedia.

Provided herein are methods shifting the isoelectric profile of a recombinant protein product and the use of such methods in the manufacture of recombinant protein products. Also provided are recombinant protein products produced by such methods.

Alexion Pharmaceuticals | Date: 2015-10-13

Provided herein are methods of replicating a large scale eculizumab production cell culture in a small scale culture.

Alexion Pharmaceuticals | Date: 2015-11-03

A bone delivery conjugate having a structure selected from the group consisting of: A) X-D

The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and/or an inhibitor of interferon alpha, and the use of the compositions in methods for treating or preventing Degos disease in a subject. In some embodiments, the inhibitor is an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or to a biologically-active fragment of C5 such as C5a or C5b. In some embodiments, the inhibitor is an antibody, or an antigen-binding fragment thereof, that binds to interferon alpha or to an interferon alpha receptor.

Alexion Pharmaceuticals | Date: 2015-03-13

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpastures syndrome, and chronic obstructive pulmonary disease.

Discover hidden collaborations